Shares of Sage Therapeutics fell more than 50% on Monday after the Food and Drug Administration approved the biotech company's oral drug zuranolone for postpartum depression, but not for major ...

We are living through one of the most violent stock market climates in modern history… This isn’t your average market pullback. This is whiplash with a capital W. And it puts us in rare company.

Shares of Compass Pathways Plc. (CMPS) slumped 47% on Monday afternoon after the results from the late-stage trials of COMP360 in treatment-resistant depression fell short of market expectations.

Sage shares surge over 35% after acquisition announcement Supernus to save up to $200 million annually from shared expenses Deal expected to close in Q3 2025, accretive by 2026 The deal will help ...

Axsome Therapeutics reported strong Q1 2025 earnings, with revenue and EPS beats driven by Auvelity and Sunosi, despite high SG&A expenses and net loss. Auvelity shows promising growth in the ...

The S&P 500 and the Dow Jones Industrial Average indices appear to be tracing a concerning pattern of consecutive steep declines, a phenomenon last witnessed during the Great Depression. What Happened ...

Johnson & Johnson’s decision to splash out $14.6 billion on its purchase of Intra-Cellular Therapies earlier this year was largely driven by the acquired company's rising antipsychotic star Caplyta ...

Company has continued to advance its previously announced plan to obtain FDA approval for two new drugs and to develop a network of clinics focused on neuroplastic therapies to treat severe and ...